Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, First-in-Human Study to Evaluate CANNABICS RCC-33

Next Previous
X
Search
Trial Profile

A Phase 1/2a, First-in-Human Study to Evaluate CANNABICS RCC-33

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RCC-33 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; First in man
  • Sponsors CNBX Pharmaceuticals

    • Most Recent Events

    • 31 May 2022 According to a CNBX Pharmaceuticals media release, this study is expected to be launched by end of 2023.
    • 21 Oct 2021 EDISON Group issued a Healthcare QuickView publication on the company prepared by Analyst Will Manuel.The publication details Company plans for Phase I/II clinical studies for RCC-33.
    • 17 Mar 2021 According to a Cannabics Pharmaceuticals media release, the company is aiming to schedule a pre-IND meeting with the US Food and Drug Administration by next quarter and start this study by the beginning of 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top